Skip to main content

Table 1 Results of baseline quantitative sensory testing.

From: Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study

Variable

 

ARA 290*

Placebo

Nerve fibers involved

Change

Number of patients (%)

Change

Number of patients (%)

Cold detection threshold

Aδ and C

Decrease

7 (64)

Decrease

9 (90)

Warm detection threshold

Aδ and C

Decrease

7 (64)

Decrease

6 (60)

Thermal sensory limen

Aδ and C

Decrease

3 (27)

Decreased, increased

2 (20), 1 (10)

Paradoxical heat sensation

Aδ

Decrease

1 (9)

0

Cold pain threshold

Aδ and C

0

Increase

1 (10)

Heat pain threshold

C

Decrease, increase

2 (18), 1 (9)

Decrease, increase

1 (10), 2 (20)

Mechanical detection threshold

Aβ

Decrease, increase

2 (18), 1 (9)

Decrease

1 (10)

Mechanical pain threshold

Aβ

Decrease

2 (18)

Decrease

3 (30)

Mechanical pain sensitivity

Aβ + C

Decrease

1 (9)

Increase

2 (20)

Dynamic mechanical allodynia

Aβ

Increase

1 (9)

Increase

4 (40)

Windup ratio

Aδ and C

0

Increase

1 (10)

Vibration detection threshold

Aβ

Decrease

6 (55)

Decrease

6 (60)

Pressure pain threshold

Aδ and C

Increase

2 (18)

Increase

8 (80)

  1. *One patient in the ARA 290 treatment arm refused QST. Patients in both treatment groups showed functional impairment in the function of both small fibers (Aδ and C) as well as larger sensory fibers (Aβ). Data are expressed as either increased or decreased function in those patients deviating 2 or more standard deviations from measurements obtained from a normal population.